Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients

Kazumichi Matsushita^1*, Keitaro Sato², Kohei Unagami¹, Kosaku Nitta², Kiichiro Tago¹

¹Matsushita Nephrology Clinic, Yamanashi, Japan.
²Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan.

DOI: 10.4236/ijcm.2014.520169                

Abstract

Back ground: There are no published clinical data in hemodialysis (HD) patients with mineral bone disorder (CKD-MBD) regarding the effect of sevelamer hydrochloride on the absorption of the oral calcitriol. Objectives: The aim of the present study was to determine the association of the sevelamer hydrochloride and serum 1-25(OH)₂D concentration during oral calcitriol therapy. Methods: This was a before-and-after study in HD patients. Forty-six patients co-administered with phosphate-binder and calcitriol for CKD-MBD therapy took lanthanum carbonate (LC) and sevelamer hydrochloride (SH) for 4 weeks, respectively with calcitriol. The serum 1-25(OH)₂D concentration was assessed after each period. Results: Serum 1-25(OH)₂D concentration was significantly reduced with co-administration of SH compared to LH (mean, calcitriol with LC→SH: 19.9 pg/ml → 14.2 pg/ml, p < 0.001). The mean dosage of calcitriol, LH and SH was 0.32 mcg/day, 1443 mg/day and 3897 mg/day, respectively. Conclusion: SH significantly reduced serum 1-25(OH)₂D concentrations after oral calcitriol administration compared to LH in HD patients. When we use SH as a phosphate binder with calcitriol for HD patients with CKD-MBD, we should consider the inhibitory effect of SH on oral calcitriol absorption.

Keywords

Hemodialysis, Calcitriol, Sevelamer Hydrochrolide, Lanthanum Carbonate, Bioavailability

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Priè, D., Ureña Torres, P. and Friedlander, G. (2009) Latest Findings in Phosphate Homeostasis. Kidney International, 75, 882-889. http://dx.doi.org/10.1038/ki.2008.643
[2]	Mathew, S., Tustison, K.S., Sugatani, T., Cahudhary, L.R. and Hruska, K.A. (2008) The Mechanism of Phosphorus as a Cardiovascular Risk Factor in CKD. Journal of the American Society of Nephrology, 19, 1092-1105. http://dx.doi.org/10.1681/ASN.2007070760
[3]	Kestenbaum, B., Sampson, J.N., Rudser, K.D., Patterson, D.J., Young, S.L., et al. (2005) Serum Phosphate Levels and Mortality Risk among People with Chronic Kidney Disease. Journal of the American Society of Nephrology, 16, 520-552. http://dx.doi.org/10.1681/ASN.2004070602
[4]	Voormolen, N., Noordzij, M., Grootendorst, D.C., Beetz, I., Sijpkens, Y.W., van Manen, J.G., et al. (2007) High Plasma Phosphate as a Risk Factor for Decline in Renal Function and Mortality in Pre-Dialysis Patients. Nephrology Dialysis Transplantation, 22, 2909-2916. http://dx.doi.org/10.1093/ndt/gfm286
[5]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, 76, S1-S130.
[6]	National Kidney Foundation (2003) KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. American Journal of Kidney Diseases, 42, S1-S201. http://dx.doi.org/10.1016/S0272-6386(03)00905-3
[7]	Fukagawa, M., Yokoyama, K., Koiwa, F., Taniguchi, M., Shoji, T., Kazama, J.J., et al. (2013) Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 17, 247-288. http://dx.doi.org/10.1111/1744-9987.12058
[8]	Benini, O., D’Alessandro, C., Gianfaldoni, D. and Cupisti, A. (2011) Extra-Phosphate Load from Food Additives in Commonly Eaten Foods: A Real and Insidious Danger for Renal Patients. Journal of Renal Nutrition, 21, 303-308. http://dx.doi.org/10.1053/j.jrn.2010.06.021
[9]	Pohlmeier, R. and Vienken, J. (2001) Phosphate Removal and Hemodialysis Conditions. Kidney International. Supplement, 78, S190-S194. http://dx.doi.org/10.1046/j.1523-1755.2001.07812.x
[10]	Bushinsky, D.A. (2010) Contribution of Intestine, Bone, Kidney, and Dialysis to Extracellular Fluid Calcium Content. Clinical Journal of the American Society of Nephrology, 5, S12-S22. http://dx.doi.org/10.2215/CJN.05970809
[11]	Slatopolsky, E.A., Burke, S.K. and Dillon, M.A. (1999) RenaGel, a Nonabsorbed Calcium- and Aluminum-Free Phosphate Binder, Lowers Serum Phosphorus and Parathyroid Hormone. Kidney International, 55, 299-307. http://dx.doi.org/10.1046/j.1523-1755.1999.00240.x
[12]	Al-Baaj, F., Speake, M. and Hutchison, A.J. (2005) Control of Serum Phosphate by Oral Lanthanum Carbonate in Patients Undergoing Haemodialysis and Continuous Ambulatory Peritoneal Dialysis in a Short-Term, Placebo-Controlled Study. Nephrology Dialysis Transplantation, 20, 775-782. http://dx.doi.org/10.1093/ndt/gfh693
[13]	Suki, W.N., Zabaneh, R., Cangiano, J.L., Reed, J., Fisher, D., Garrett, L., et al. (2007) Effects of Sevelamer and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients. Kidney International, 72, 1130-1137. http://dx.doi.org/10.1038/sj.ki.5002466
[14]	Wilson, R., Zhang, R.P., Smyth, M. and Pratt, R. (2009) Assessment of Survival in a 2-Year Comparative Study of Lanthanum Carbonate versus Standard Therapy. Current Medical Research and Opinion, 25, 3021-3028. http://dx.doi.org/10.1185/03007990903399398
[15]	Braunlin, W., Zhorov, E., Guo, A., Apruzzese, W., Xu, Q., Hook, P., et al. (2002) Bile Acid Binding to Sevelamer HCl. Kidney International, 62, 611-619. http://dx.doi.org/10.1046/j.1523-1755.2002.00459.x
[16]	US Prescribing Information Renagel (Sevelamer hydrochloride), Silver Spring, MD, USA, Center for Drug Evaluation and Research.
[17]	Pierce, D., Hossack, S., Poole, L., Robinson, A., Van Heusen, H., Martin, P. and Smyth, M. (2011) The Effect of Sevelamer Carbonate and Lanthanum Carbonate on the Pharmacokinetics of Oral Calcitriol. Nephrology Dialysis Transplantation, 26, 1615-1621. http://dx.doi.org/10.1093/ndt/gfq598
[18]	Brezina, B., Qunibi, W.Y. and Nolan, C.R. (2004) Acid Loading during Treatment with Sevelamer Hydrochloride: Mechanisms and Clinical Implications. Kidney International, 66, SS39-SS45. http://dx.doi.org/10.1111/j.1523-1755.2004.09007.x
[19]	Plone, M.A., Petersen, J.S., Rosenbaum, D.P. and Burke, S.K. (2002) Sevelamer, a Phosphate Binding Polymer, Is a Non-Absorbed Compound. Clinical Pharmacokinetics, 41, 517-523. http://dx.doi.org/10.2165/00003088-200241070-00005
[20]	Wrong, O. and Harland, C. (2007) Sevelamer and Other Anion-Exchange Resins in the Prevention and Treatment of Hyperphosphatemia in Chronic Renal Failure. Nephron Physiology, 107, 17-33.
[21]	Wrong, O.M. and Harland, C.E. (2005) Sevelamer-Induced Acidosis. Kidney International, 67, 776-777. http://dx.doi.org/10.1111/j.1523-1755.2005.67142_2.x
[22]	Chertow, G.M., Burke, S.K. and Raggi, P. (2002) Sevelamer Attenuates the Progression of Coronary and Aortic Calcification in Hemodialysis Patients. Kidney International, 62, 245-252. http://dx.doi.org/10.1046/j.1523-1755.2002.00434.x
[23]	Shoji, T., Masakane, I., Watanabe, Y., Iseki, K., Tsubakihara, Y., et al. (2011) Elevated Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology, 6, 1112-1120. http://dx.doi.org/10.2215/CJN.09961110
[24]	Shigematsu, T., Lanthanum Carbonate Group (2008) Multicenter Prospective Randomized, Double-Blind Comparative Study between Lanthanum Carbonate and Calcium Carbonate as Phosphate Binders in Japanese Hemodialysis Patients with Hyperphosphatemia. Clinical Nephrology, 70, 404-410. http://dx.doi.org/10.5414/CNP70404
[25]	Levine, B.S. and Song, M. (1996) Pharmacokinetics and Efficacy of Pulse Oral versus Intravenous Calcitriol in Hemodialysis Patients. Journal of the American Society of Nephrology, 7, 488-496.
[26]	Wald, R., Tentori, F., Tighiouart, H., Zager, P.G. and Miskulin, D.C. (2007) Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a Large Dialysis Network. American Journal of Kidney Diseases, 49, 257-266. http://dx.doi.org/10.1053/j.ajkd.2006.11.027
[27]	London, G.M., Guérin, A.P., Verbeke, F.H., Pannier, B., Boutouyrie, P., Marchias, S.J. and Mëtivier, F. (2007) Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency. Journal of the American Society of Nephrology, 18, 613-620. http://dx.doi.org/10.1681/ASN.2006060573
[28]	Wolf, M., Shah, A., Gutierrez, O., Ankers, E., Monroy, M., Tamez, H., et al. (2007) Vitamin D Levels and Early Mortality among Incident Hemodialysis Patients. Kidney International, 72, 1004-1013. http://dx.doi.org/10.1038/sj.ki.5002451